血凝酶联合化疗治疗恶性胸腔积液的疗效观察  

Treatment of malignant pleural effusion with hemocoagulase atrox and chemotherapy

作　　者：周伟[1] 王兴远[1] 江波[1] 李程[1] 应伟[1] 汪建[1] 

机构地区：[1]广安市人民医院肿瘤科,四川广安638000

出　　处：《西部医学》2011年第9期1663-1664,1667,共3页Medical Journal of West China

摘　　要：目的观察血凝酶联合顺铂、白介素-2对恶性胸腔积液的治疗效果。方法采用胸腔穿刺,置入中心静脉导管引流,灌注血凝酶联合顺铂、白介素-2治疗恶性胸腔积液患者34例,观察有效率。结果近期有效率(CR+PR)91.2%,观察12周后有效率79.4%。结论血凝酶联合顺铂、白介素-2经闭式引流治疗恶性胸腔积液疗效好,不良反应轻,适合临床推广。Objective To observe the efficacy and safety of the chemotherapy and hemocoagulase atrox by the thorax catheterization in treatment of malignant pleural effusion.Methods 34 patients with the malignant pleural effusion were treated with closed drainage of central venous catheter followed by infection of IL2,hemocoagulase atrox,and DDP（40 mg/m2 for weekly,1 cycle for 3～4 weeks）.Results The total effective rate was 91.2 % with 14 cases of CR and 17 cases of PR after 4weeks,and was 79.4% after 12 weeks.Conclusion The chemotherapy combined with intracavity hemocoagulase atrox injection by thorax catheterization is effective and safe in clinical.

关 键 词：恶性胸腔积液 中心静脉导管 血凝酶 胸腔灌注化疗 疗效 

分 类 号：R73[医药卫生—肿瘤]